All Products & Services Research Use Only (RUO) CE-Marked Assays View all products

Wall Charts

Hematologic Malignancy Testing Algorithm

Clonality Testing Strategy

Notice: Acute Myeloid Leukemia (AML) The FDA has made it clear that a FLT3 companion diagnostic is required for approval of any FLT3-targeted or FLT3-stratified therapy. LabPMM is the only clinical laboratory with access to the patents required to develop and offer a FLT3 companion diagnostic for worldwide use(excluding Japan).

Personalized Medicine & IVS
Invivoscribe is a leading provider of clinically-validated CE-marked in vitro diagnostic products. Through our subsidiary, LabPMM, we provide worldwide access to molecular biomarker testing, which enables pharmaceutical companies to bring to the market new targeted treatments, and allows physicians to better determine optimal treatment for their patients.

Research & Biotechnology
Development & Partnering
Companion Diagnostics

Invivoscribe develops revolutionary approach to manage biomarkers and associated licenses
This technology will simplify licensing, increase access to biomarker testing, while ensuring the ongoing strength and value of intellectual property around biomarkers. We believe the approach will be embraced by all stakeholders.

TCRG Gene Rearrangement Assay 2.0

Our improved assay for rapid TCRG clonality assessment detects the vast majority of T Cell Receptor gamma gene rearrangements with a single multiplex master mix, and generates a single Gaussian distribution in a size range consistent with testing FFPE specimens. Contact us or visit our online catalog to learn more, or visit Poster Number H07, Development of a Single Tube TCRG Assay, at the 2011 AMP Annual Meeting. 

BCR/ABL Lyophilized Cell Controls and RNA Dilution Sets are available

We have released our BCR/ABL b3a2, b2a2, and e1a2 Lyophilized Cell Controls and RNA Dilution Sets.

Contact us to learn more, or visit Poster Number H10, Lyophilized Cell Controls for BCR-ABL Quantitative RT-PCR, at the 2011 AMP Annual Meeting

In the News

12/26/2011 The New York Times
A Push to Tie New Drugs to Testing by Andrew Pollack

02/23/2011 Pharmacogenomics Reporter
Novartis, Invivoscribe to Develop Companion Test for Acute Myeloid Leukemia Rx Midostaurin

02/21/2011 BioCentury
Invivoscribe Technologies Inc., Novartis deal

Press Releases
February 15, 2011
Invivoscribe Announces Collaboration Agreement to Develop Companion Diagnostic

Our growth continues...

Our San Diego headquarters has doubled, building out two additional suites for cGMP manufacturing and shipping. LabPMM has also expanded here in San Diego, and LabPMM GmbH, took delivery of our new European reference laboratory in Martinsried, Germany on September 30, 2011.

View all News